Aeglea BioTherapeutics In... (AGLE)
NASDAQ: AGLE
· Real-Time Price · USD
12.01
0.75 (6.66%)
At close: Nov 27, 2023, 9:00 PM
6.66% (1D)
| Bid | n/a |
| Market Cap | 48.63M |
| Revenue (ttm) | 1.05M |
| Net Income (ttm) | -294.43M |
| EPS (ttm) | -74.15 |
| PE Ratio (ttm) | -0.1619689817936615 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 43,238 |
| Avg. Volume (20D) | 59,537 |
| Open | 10.87 |
| Previous Close | 11.26 |
| Day's Range | 10.69 - 12.34 |
| 52-Week Range | 2.66 - 24.00 |
| Beta | 2.57 |
About AGLE
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, w...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 7, 2016
Employees 69
Stock Exchange NASDAQ
Ticker Symbol AGLE
Website https://www.aeglea.com